Sino Medical Sciences Technology Inc. (688108.SS)
CNY 9.7
(-0.31%)
CNY 9.7
(-0.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 324.17 Million CNY | 79.96% |
| 2022 | 180.13 Million CNY | 14.06% |
| 2021 | 157.92 Million CNY | 13.1% |
| 2020 | 139.63 Million CNY | 30.36% |
| 2019 | 107.1 Million CNY | 2.18% |
| 2018 | 104.82 Million CNY | 1.16% |
| 2017 | 103.62 Million CNY | 32.74% |
| 2016 | 78.06 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 391.42 Million CNY | -1.06% |
| 2024 Q1 | 395.62 Million CNY | 22.04% |
| 2024 Q3 | 381.22 Million CNY | -2.61% |
| 2023 Q4 | 324.17 Million CNY | 32.14% |
| 2023 FY | 324.17 Million CNY | 79.96% |
| 2023 Q3 | 245.31 Million CNY | 16.23% |
| 2023 Q2 | 211.05 Million CNY | 30.45% |
| 2023 Q1 | 161.79 Million CNY | -10.18% |
| 2022 Q4 | 180.13 Million CNY | 1.94% |
| 2022 Q2 | 192.21 Million CNY | 10.94% |
| 2022 Q1 | 173.26 Million CNY | 9.71% |
| 2022 Q3 | 176.7 Million CNY | -8.07% |
| 2022 FY | 180.13 Million CNY | 14.06% |
| 2021 Q2 | 155.22 Million CNY | -2.59% |
| 2021 Q1 | 159.35 Million CNY | 14.12% |
| 2021 FY | 157.92 Million CNY | 13.1% |
| 2021 Q4 | 157.92 Million CNY | 18.64% |
| 2021 Q3 | 133.11 Million CNY | -14.24% |
| 2020 Q4 | 139.63 Million CNY | 38.14% |
| 2020 Q3 | 101.08 Million CNY | -26.84% |
| 2020 Q2 | 138.17 Million CNY | 63.89% |
| 2020 Q1 | 84.3 Million CNY | -21.29% |
| 2020 FY | 139.63 Million CNY | 30.36% |
| 2019 Q4 | 107.1 Million CNY | 10.61% |
| 2019 FY | 107.1 Million CNY | 2.18% |
| 2019 Q3 | 96.83 Million CNY | -14.79% |
| 2019 Q1 | 87.47 Million CNY | -16.55% |
| 2019 Q2 | 113.63 Million CNY | 29.91% |
| 2018 Q4 | 104.82 Million CNY | 0.0% |
| 2018 Q1 | 104.82 Million CNY | 0.0% |
| 2018 FY | 104.82 Million CNY | 1.16% |
| 2017 FY | 103.62 Million CNY | 32.74% |
| 2016 FY | 78.06 Million CNY | 0.0% |